ESR1 and neoplasm: It is, therefore, conceivable that in ER-positive normal-weight or overweight patients undergoing endocrine treatment, the high levels of testosterone mainly affect tumour relapse through an alternative estrogen/ER signaling, likely by androgen/AR proliferative axis or by favoring proliferation along growth factors pathway [35, 36].